Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Schuler

Showing results (211-220 of 298) with videos related to

Pageof 30
Sort By:
Nature Medicine|April 30, 2024
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trialMartin Schuler, Kristof Cuppens, Till Plönes, et al.
Scientific Reports|October 20, 2022
Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CTMaja Guberina, Ken Herrmann, Christoph Pöttgen, et al.
PLOS Digital Health|July 8, 2026
Large language models enable prognostic stratification of cancer patients using real-world clinical notesNiklas Kiermeyer, Tim Lenfers, Amin Dada, et al.
Histopathology|March 15, 2020
Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesotheliomaAgnes Bilecz, Paul Stockhammer, Dirk Theegarten, et al.
BMJ Open|March 27, 2025
NeoTRACK trial: <u>Neo</u>adjuvant <u>T</u>i<u>R</u>agolumab, <u>A</u>tezolizumab and <u>C</u>hemotherapy - dissection of IO- efficacy in NSCLC by longitudinal trac<u>K</u>ing - protocol of a non-randomised, open-label, single-arm, phase II studyRomina M Roesch, Johannes Schnorbach, Laura V Klotz, et al.
Cancer Immunology, Immunotherapy : CII|October 2, 2024
Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical dataPatrick Reimann, Ilektra-Antonia Mavroeidi, Jonathan Burghofer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 15, 2023
SUV<sub>max</sub> Above 20 in <sup>18</sup>F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown PrimaryGregor Zaun, Manuel Weber, Martin Metzenmacher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human StudyDejan Juric, Jordi Rodon, Josep Tabernero, et al.
Nature Genetics|November 22, 2016
Inactivation of Capicua drives cancer metastasisRoss A Okimoto, Frank Breitenbuecher, Victor R Olivas, et al.
Clinical Colorectal Cancer|August 2, 2020
Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX TrialStefan Kasper, Johannes Meiler, Heike Knipp, et al.
Pageof 30

Showing results (211-220 of 298) with videos related to

Sort By:
Pageof 30
Nature Medicine|April 30, 2024
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trialMartin Schuler, Kristof Cuppens, Till Plönes, et al.
Scientific Reports|October 20, 2022
Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CTMaja Guberina, Ken Herrmann, Christoph Pöttgen, et al.
PLOS Digital Health|July 8, 2026
Large language models enable prognostic stratification of cancer patients using real-world clinical notesNiklas Kiermeyer, Tim Lenfers, Amin Dada, et al.
Histopathology|March 15, 2020
Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesotheliomaAgnes Bilecz, Paul Stockhammer, Dirk Theegarten, et al.
BMJ Open|March 27, 2025
NeoTRACK trial: <u>Neo</u>adjuvant <u>T</u>i<u>R</u>agolumab, <u>A</u>tezolizumab and <u>C</u>hemotherapy - dissection of IO- efficacy in NSCLC by longitudinal trac<u>K</u>ing - protocol of a non-randomised, open-label, single-arm, phase II studyRomina M Roesch, Johannes Schnorbach, Laura V Klotz, et al.
Cancer Immunology, Immunotherapy : CII|October 2, 2024
Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical dataPatrick Reimann, Ilektra-Antonia Mavroeidi, Jonathan Burghofer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 15, 2023
SUV<sub>max</sub> Above 20 in <sup>18</sup>F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown PrimaryGregor Zaun, Manuel Weber, Martin Metzenmacher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human StudyDejan Juric, Jordi Rodon, Josep Tabernero, et al.
Nature Genetics|November 22, 2016
Inactivation of Capicua drives cancer metastasisRoss A Okimoto, Frank Breitenbuecher, Victor R Olivas, et al.
Clinical Colorectal Cancer|August 2, 2020
Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX TrialStefan Kasper, Johannes Meiler, Heike Knipp, et al.
Pageof 30